Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab

Aliment Pharmacol Ther. 2018 Apr;47(7):1040-1041. doi: 10.1111/apt.14541.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Immunosuppressive Agents*
  • Inflammatory Bowel Diseases*
  • Infliximab

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • vedolizumab
  • Infliximab
  • Adalimumab